ConMed Corporation Responds To Activist Investor

Published: Nov 13, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ConMed responds to a challenge from activist investor group Voce Capital Management, citing "the strong operating performance delivered by ConMed over the past several years." ConMed (NSDQ:CNMD) today responded to a long and critical letter from Voce Capital Management issued last week that demanded steps toward a strategic exit and the end "a culture of nepotism, patronage and dystopian corporate governance." Voce, which owns a roughly 1% stake in ConMed, described the company as run and ruined by the Corasanti family, highlighting several high-level officers with ties to company founder, former CEO and current chairman and vice chairman Eugene Corasanti, who in 2006 handed the corner office to his son, Joseph Corasanti.

Help employers find you! Check out all the jobs and post your resume.

Back to news